Generation of Chikungunya Virus-Like Particles Using Baculovirus Expression System in Insect Cells
JoVE Encyclopedia of Experiments
Immunology
0 views • 3:05 min • July 8th, 2025
Loading...
Overview
This article describes the production of Chikungunya virus-like particles (VLPs) using recombinant baculoviruses in Sf9 insect cells. The process involves the expression of structural proteins, their processing, and the subsequent release of VLPs for immunopathology studies.
Key Study Components
Area of Science
- Virology
- Cell Biology
- Immunology
Background
- Chikungunya virus is a significant human pathogen.
- VLPs are non-infectious and useful for vaccine development.
- Recombinant baculoviruses are effective for protein expression in insect cells.
- Understanding VLP production can aid in immunological research.
Purpose of Study
- To produce Chikungunya VLPs for research purposes.
- To investigate the processing of viral proteins in insect cells.
- To prepare VLPs for use in immunopathology studies.
Methods Used
- Infection of Sf9 cells with recombinant baculoviruses.
- Incubation at 28 degrees Celsius for protein expression.
- Use of trypan blue exclusion for cell viability assessment.
- Centrifugation and filtration to purify VLPs.
Main Results
- Successful production of Chikungunya VLPs in Sf9 cells.
- Characterization of protein processing and maturation.
- Isolation of VLPs suitable for further immunological studies.
- Demonstrated viability of Sf9 cells post-infection.
Conclusions
- Chikungunya VLPs can be efficiently produced in insect cell systems.
- The methodology allows for the study of viral protein processing.
- VLPs hold potential for future vaccine development and research.
Frequently Asked Questions
What are Chikungunya virus-like particles?
Chikungunya VLPs are non-infectious structures made of viral proteins.
How are VLPs produced?
VLPs are produced by infecting Sf9 cells with recombinant baculoviruses.
What is the significance of VLPs?
VLPs are important for vaccine development and immunological studies.
What role do baculoviruses play in this process?
Baculoviruses facilitate the expression of viral structural proteins in insect cells.
How is cell viability assessed during the process?
Cell viability is assessed using trypan blue exclusion method.
What happens to the VLPs after production?
VLPs are purified and can be used for immunopathology studies.
Executive Industry Relevance
Production of Chikungunya virus-like particles (VLPs) in insect cells using the baculovirus expression system enables scalable generation of non-infectious viral structures for immunopathology and vaccine research. This platform supports early-stage target validation and de-risks antigen selection by providing structurally relevant VLPs without infectious risk. The approach is positioned for portfolio teams seeking robust, reproducible antigen sources for downstream translational studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of Chikungunya structural antigens in a controlled, non-infectious format.
- Supports biological de-risking by providing authentic viral envelope protein assemblies.
- Facilitates predictive confidence in antigenicity and immunogenicity assessments.
Screening & Assay Development
- Provides standardized VLP preparations for assay calibration and validation.
- Enables reproducible quantitative outputs for immunological screening workflows.
- Supports scalable production for high-throughput screening and platform reuse.
Translational & Preclinical Research
- Delivers VLPs suitable for immunopathology studies and preclinical immunogenicity models.
- Aligns with translational biomarker development by mimicking native viral structures.
- Supports continuity from antigen discovery through preclinical validation phases.
Pipeline & Workflow Integration
This VLP generation method integrates into the discovery-to-preclinical continuum, providing a bridge from antigen identification to immunological evaluation.
- Discovery Biology: Supports hypothesis testing on viral antigen structure and immune recognition.
- Screening: Supplies reproducible VLPs for assay development and comparative immunogenicity studies.
- Analytics: Enables quantitative measurement of VLP yield and purity for process optimization.
- Translational Research: Provides material for preclinical immunopathology and biomarker alignment studies.
- Enterprise Reuse: Establishes a reusable platform for VLP production across viral targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in antigen selection and immunogenicity.
- Operational Value: Standardizes VLP production for reproducibility and scalability.
- Strategic Value: Reduces biological risk and supports efficient go/no-go decisions in vaccine R&D.
- Portfolio Impact: Enables risk-adjusted prioritization of antigen candidates for advancement.
Implementation Considerations
- Requires expertise in baculovirus vector design and insect cell culture.
- Needs access to spinner flask systems and cell viability assessment tools.
- Demands cross-team standardization for VLP purification and quality control.
- Adaptation may be needed for different viral gene cassettes or cell lines.
- Yield and purity are influenced by infection parameters and cell health.
Biopharma FAQs
Why does null hypothesis testing matter for VLP-based antigen validation?
Null hypothesis testing enables teams to rigorously assess whether observed immunogenic responses to Chikungunya VLPs are statistically significant compared to controls, supporting confident target validation and reducing false positives in antigen selection.
How does independent variable isolation fit the VLP production workflow?
Isolating variables such as infection multiplicity and incubation time allows for controlled optimization of VLP yield and quality, ensuring that observed effects are attributable to specific process parameters rather than confounding factors.
What do quantitative VLP yield measurements enable in R&D?
Quantitative measurement of VLP yield and purity provides actionable data for process optimization, batch-to-batch consistency, and supports downstream assay calibration and immunogenicity comparisons.
Why are replication requirements critical for cross-functional VLP studies?
Replication ensures that VLP production and immunological outputs are reproducible across batches and teams, facilitating reliable data sharing and collaborative decision-making in multi-site R&D environments.
What statistical analysis capabilities are required before VLP implementation?
Robust statistical analysis is needed to compare VLP yields, purity, and immunogenicity across experimental conditions, enabling data-driven process improvements and supporting regulatory documentation for translational studies.
10:18
Making Conjugation-induced Fluorescent PEGylated Virus-like Particles by Dibromomaleimide-disulfide Chemistry
Related Videos
0 Views
07:02
Quantifying Human Norovirus Virus-like Particles Binding to Commensal Bacteria Using Flow Cytometry
Related Videos
0 Views
05:15
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
Related Videos
0 Views
09:41
A Method For Production of Recombinant mCD1d Protein in Insect Cells.
Related Videos
0 Views
03:09
A Technique for the Generation of Influenza Virus-Like Particles via a Mammalian System
Related Videos
0 Views
12:18
Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
Related Videos
0 Views
13:52
Efficient Production and Purification of Recombinant Murine Kindlin-3 from Insect Cells for Biophysical Studies
Related Videos
0 Views
06:17
Expression and Purification of Virus-like Particles for Vaccination
Related Videos
0 Views
12:09
Transient Expression and Cellular Localization of Recombinant Proteins in Cultured Insect Cells
Related Videos
0 Views
11:12
Transient Expression of Foreign Genes in Insect Cells (sf9) for Protein Functional Assay
Related Videos
0 Views
Last updated: 1 August 2026